496848-48-7

Basic information

• Product Name: (4S)-4-hydroxyl-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxyl-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl)dihydrofuran-2(3H)-one
• CAS NO: 496848-48-7
• Molecular Weight: 352.471
• Mol File: 496848-48-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4S)-4-hydroxyl-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxyl-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl)dihydrofuran-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-hydroxyl-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxyl-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl)dihydrofuran-2(3H)-one(496848-48-7)
• EPA Substance Registry System: (4S)-4-hydroxyl-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxyl-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl)dihydrofuran-2(3H)-one(496848-48-7)

Safety Data

• Hazardous Substances Data: 496848-48-7(Hazardous Substances Data)

Upstream product

• 142037-79-4 andrographolide 

Downstream Products

• 4176-97-0 14-deoxyandrographolide 

Relevant articles and documents

Synthesis of andrographolide analogues and their neuroprotection and neurite outgrowth-promoting activities

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease and remains incurable. Currently, neuronal injury and synapse loss have been considered to be main features in the pathophysiology of AD. Thus, modulation of neuronal survival and neurite outgrowth may represent an efficient strategy for the treatment of AD. Based on the isolates from the traditional medicine Andrographis paniculata, a series of andrographolide analogues were prepared and evaluated for the neuroprotection and neurotrophic activity. Two compounds (3 and 12) could effectively inhibit LPS-induced NO production and iNOS expression as well as proinflammatory cytokines TNF-α and IL-6. Moreover, pretreatment with 3 and 12 could protect neurons against microglia-mediated neurotoxicity. Further, H2O2 ? and 6-OHDA induced neurotoxicity in PC12 cells were also attenuated by the novel 12. Our next study indicated that compounds 1, 4 and 10 promoted NGF-induced neurite outgrowth in PC12 cells, with 10 the most potent. To clarify the underlying mechanisms of active compounds (3, 10 and 12), system pharmacology was employed. The results revealed that muscarinic acetylcholine receptors (mAChRs) may be the main targets of 12 against AD, while thyroid hormone signaling pathway was involved in the mechanisms of 10. These study point to the therapeutic potential of andrographolide analogues against AD.